AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform

Core Viewpoint - AbbVie Inc. is highlighted as a strong long-term investment option, particularly for retirement, following positive fourth-quarter results and an optimistic outlook from Cantor Fitzgerald with a price target of $250 [1]. Financial Performance - AbbVie reported record net sales of $16.61 billion for the fourth quarter, marking a 10% increase year-over-year, driven by an 18.3% rise in immunology portfolio revenues to $8.63 billion [2]. - For the full year, AbbVie's net revenues reached $61.16 billion, reflecting an 8.6% year-over-year growth, primarily due to a 14% increase in the immunology portfolio [3]. - The diluted earnings per share (EPS) for the fourth quarter was $1.02, while the adjusted diluted EPS for the full year was $10, indicating a slight decrease of 1.2% year-over-year [3]. Future Outlook - AbbVie anticipates its full-year 2026 earnings per share to be between $14.37 and $14.57, indicating a positive growth trajectory [3]. Strategic Moves - During the quarter, AbbVie announced an agreement to acquire a device manufacturing facility in Tempe, along with associated intellectual property, which is expected to bolster the development of next-generation immunology and neuroscience medicines [4]. Company Overview - AbbVie is a global research-driven biopharmaceutical company focused on discovering and developing treatments for complex, chronic diseases across various fields, including immunology, oncology, neuroscience, eye care, and aesthetics [4].